Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (78)	9/14/1998 11:22:00 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1475

Not really on topic, and I certainly don't endorse the Enzo approach, but...... biz.yahoo.com "strong promise for development of a new approach to treat certain undesirable immune responses, including those elicited against viral vectors for gene delivery" A few months ago, I contacted an old boss, Patrick Trown of Onyx Pharmaceuticals, and recommended that they contact BTRN regarding the elimination of immune response to adenovirus vectors. Dr. Trown indicated that antibody responses, while they existed, weren't a problem for Onyx.